샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793924

세계의 요로상피암 진단 시장

Urothelial Carcinoma Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

요로상피암 진단 세계 시장은 2030년까지 28억 달러에 달할 전망

2024년에 16억 달러로 추정되는 요로상피암 진단 세계 시장은 2024년부터 2030년까지 CAGR 9.8%로 성장하여 2030년에는 28억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 시약 및 키트는 CAGR 8.1%를 기록하며 분석 기간 종료시에는 16억 달러에 달할 것으로 예측됩니다. 기기 부문의 성장률은 분석 기간 동안 CAGR 12.1%로 추정됩니다.

미국 시장은 4억 3,970만 달러로 추정, 중국은 CAGR 13.1%로 성장 예측

미국의 요로상피암 진단 시장은 2024년에는 4억 3,970만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 5억 6,690만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 7.2%와 8.5%로 예측됩니다. 유럽에서는 독일이 CAGR 7.6%로 성장할 것으로 예측됩니다.

세계의 요로상피암 진단 시장 - 주요 동향과 촉진요인 정리

요로상피암의 조기에 정확한 진단이 임상적으로 필수적인 이유는 무엇일까?

요로상피암은 주로 방광과 요로의 다른 부분의 내벽을 침범하며, 특히 노년층에서 세계에서 가장 흔한 악성 종양 중 하나입니다. 또한, 가장 재발하기 쉬운 암 중 하나이며, 치료 후에도 재발률이 높아 환자의 예후를 개선하기 위해서는 조기에 정확한 진단이 중요합니다. 요로상피암의 가장 흔한 증상인 방광암은 혈뇨와 같은 비특이적 증상을 보이는 경우가 많으며, 이로 인해 임상 검사가 지연되는 경우가 많습니다. 이 때문에 많은 환자들은 치료가 복잡해지고 생존율이 현저히 낮아지는 진행기에 진단을 받게 됩니다. 암 병변을 조기에 발견하면 덜 침습적인 치료법을 적용할 수 있어 예후가 개선되고, 의료 시스템의 장기적인 비용 부담을 크게 줄일 수 있습니다. 또한, 방광경 검사나 요세포 검사와 같은 요로상피암 진단 절차는 기존에는 침습적이고 시간이 오래 걸리며, 때로는 결론을 내리지 못하는 경우도 있었습니다. 정확하고 덜 침습적이며 환자 친화적인 진단 도구에 대한 요구가 높아지면서 바이오마커, 분자 검사, 영상 기술의 혁신이 가속화되고 있습니다. 이러한 발전은 질병의 조기 발견뿐만 아니라 더 높은 특이성과 민감도로 재발 및 치료 효과를 모니터링하는 것을 목표로 하고 있습니다. 요로상피암에 대한 임상의와 일반인들의 인식이 높아지면서 진단 능력 향상에 대한 요구가 비뇨기암 진료의 초석이 되고 있습니다.

기술의 발전은 요로상피암 진단법을 어떻게 재정의하고 있는가?

급속한 기술 발전으로 요로상피암의 진단 환경이 재편되고 있으며, 임상의들은 보다 정확하고 덜 침습적이며 데이터가 풍부한 도구를 사용하여 요로상피암을 감지하고 모니터링할 수 있게 되었습니다. 방광경 검사나 요세포 검사와 같은 전통적인 방법은 여전히 널리 사용되고 있지만, 요로상피암과 관련된 특정 돌연변이 및 유전자 발현을 검출할 수 있는 분자진단 및 고처리량 유전체 프로파일링 기술로 보완되고 있습니다. 소변이나 혈액 내 순환 종양 DNA(ctDNA) 또는 종양 세포를 분석하는 액체 생검은 종양 생물학에 대한 실시간 인사이트를 제공하는 비침습적 대안으로 각광받고 있습니다. 차세대 염기서열 분석(NGS), 형광 in situ hybridization(FISH), PCR 기반 분석법의 개발로 눈에 보이는 종양이 발생하기 훨씬 전에 현미경 수준에서도 암종을 조기에 발견할 수 있게 되었습니다. 또한, 인공지능과 머신러닝 알고리즘이 영상 진단 및 병리 검사 워크플로우에 통합되어 악성 종양의 식별과 종양 아형 분류를 보다 정확하게 지원할 수 있게 되었습니다. 소변 바이오마커 패널은 POC(Point-of-Care) 스크리닝 솔루션을 제공하기 위해 개발되고 있습니다. 이러한 진단의 발전은 정확도와 환자의 편의성을 향상시킬 뿐만 아니라, 실용적인 분자 표적을 밝혀냄으로써 맞춤형 치료 전략을 지원할 수 있습니다. 진단 기술이 계속 발전함에 따라 요로상피암 치료는 반응적 치료에서 예방적, 예측적, 정밀 지향적 치료로 전환되고 있습니다.

역학, 위험 요인, 의료 인프라는 진단 수요에 어떤 역할을 하는가?

요로상피암 진단에 대한 수요는 역학적 패턴, 환자의 위험 프로필, 조기 발견 및 모니터링을 지원하는 국가 의료 시스템의 능력에 따라 크게 영향을 받습니다. 요로상피암은 노년층에서 많이 발생하며, 흡연, 산업화학제품 노출, 만성 요로감염 등 교정 가능한 위험요인과 유의미한 연관성이 있습니다. 전 세계 고령화, 특히 고소득 국가의 고령화는 방광암과 요로암의 발생률 증가에 기여하고 있으며, 이에 따라 광범위하고 일상적인 진단 검진의 필요성이 증가하고 있습니다. 아시아, 동유럽, 중동 등 발암물질에 대한 직업적 노출이 많은 지역에서는 발견이 늦어지거나 전문 의료에 대한 접근이 제한되어 진단에 대한 부담이 커지고 있습니다. 반대로 미국, 독일, 일본 등 의료 인프라가 잘 갖춰진 국가에서는 진단이 위험군에 대한 일상적인 비뇨기과적 평가에 포함되는 경우가 많아 조기 발견과 생존율 향상에 기여하고 있습니다. 공중보건 캠페인, 임상 가이드라인, 암 검진 보험 적용 등은 모두 환자가 언제, 어떻게 진단 평가를 받을지 결정하는 역할을 합니다. 또한, 도시와 지방, 공공 의료 부문과 민간 의료 부문 간에도 첨단 진단 기술에 대한 접근성 격차가 존재합니다. 이러한 제도적 격차를 해소하는 것은 다양한 집단에서 진단의 정확성과 공평성을 향상시키는 데 매우 중요합니다. 전 세계적으로 요로상피암에 대한 인식이 높아짐에 따라, 의료 시스템은 진단 서비스의 범위와 영향력을 확대하기 위해 인프라, 교육, 기술에 대한 투자를 늘려야 합니다.

요로상피암 진단 시장의 성장을 촉진하는 주요 요인은 무엇인가?

요로상피암 진단 시장의 성장은 진화하는 헬스케어 우선순위를 반영하는 임상적, 기술적, 정책적 차원의 요인들의 수렴에 의해 이루어집니다. 주요 요인 중 하나는 전 세계적으로 방광암과 요로암 환자가 증가하고 있으며, 특히 고령화 사회와 직업성 발암물질에 노출된 사람들 사이에서 증가하고 있다는 점입니다. 이러한 역학적 추세는 정기적인 검진과 신뢰할 수 있는 진단 도구의 필요성을 더욱 강조하고 있습니다. 소변 바이오마커, 액체 생검과 같은 비침습적 검사의 등장과 같은 기술 혁신은 진단법을 보다 환자 친화적이고 효율적으로 만들었고, 그 결과 임상 현장에서의 채택이 확대되고 있습니다. 암 조기 발견에 대한 규제 당국의 지원은 예방적 의료를 우대하는 보상 체계와 함께 공공 및 민간 의료 서비스 제공자 모두에게 첨단 진단 도구를 일상 진료에 통합할 수 있는 인센티브를 제공하고 있습니다. 개인맞춤의료와 표적치료에 대한 노력도 유전자 및 분자 프로파일을 기반으로 환자를 계층화하고 치료 방침을 결정하는 분자진단 약품에 대한 수요를 자극하고 있습니다. 제약기업과 진단기업들의 종양학 연구에 대한 연구개발은 차세대 검사 플랫폼의 개발 및 상용화를 가속화하고 있습니다. 또한, point-of-care 진단약과 원격의료 기반 병리학적 서비스의 가용성이 높아지면서 의료 서비스가 부족한 지역과 원격지에서의 접근성이 확대되고 있습니다. 이러한 요인에 더해 암 생존율 향상과 조기 개입을 통한 의료비 절감에 대한 지속적인 노력은 세계 요로상피암 진단 시장의 견조하고 지속적인 성장을 견인하고 있습니다.

부문

제품(시약·키트, 기기), 검사(소변 검사, 분자진단 검사, 바이오마커 검사, 세포 기반 검사, 영상 검사, 방광경검사, 요관경 검사), 최종사용자(병원, 진단 연구소, 조사·학술기관, 임상 연구기관 최종사용자)

조사 대상 기업 사례

  • Abbott Molecular(Abbott Laboratories)
  • Agilent Technologies
  • AroCell(IDL Biotech)
  • Becton Dickinson(BD)
  • Bio-Rad Laboratories, Inc.
  • Cepheid(Danaher)
  • F. Hoffmann-La Roche Ltd(Roche)
  • GE Healthcare
  • Illumina, Inc.
  • IDL Biotech
  • Olympus Corporation
  • Pacific Edge Limited
  • Philips Healthcare(Koninklijke Philips)
  • QIAGEN
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Vesica Health
  • Nucleix
  • Danaher Corporation

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.27

Global Urothelial Carcinoma Diagnostics Market to Reach US$2.8 Billion by 2030

The global market for Urothelial Carcinoma Diagnostics estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Reagent & Kits, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$439.7 Million While China is Forecast to Grow at 13.1% CAGR

The Urothelial Carcinoma Diagnostics market in the U.S. is estimated at US$439.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$566.9 Million by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Global Urothelial Carcinoma Diagnostics Market - Key Trends & Drivers Summarized

Why Is Early and Accurate Diagnosis of Urothelial Carcinoma Becoming a Clinical Imperative?

Urothelial carcinoma, which primarily affects the lining of the bladder and other parts of the urinary tract, has become one of the most common malignancies worldwide, particularly in aging populations. It is also among the most recurrent forms of cancer, with high relapse rates even after treatment, making early and accurate diagnosis critical to improving patient outcomes. Bladder cancer, the most common manifestation of urothelial carcinoma, often presents with nonspecific symptoms such as hematuria, which can lead to delays in clinical investigation. Because of this, many patients are diagnosed at advanced stages when treatment becomes more complex and survival rates drop significantly. Timely identification of cancerous lesions enables the application of less invasive therapies, improves prognosis, and significantly reduces the long-term cost burden on healthcare systems. Furthermore, diagnostic procedures for urothelial carcinoma, such as cystoscopy and urine cytology, have traditionally been invasive, time-consuming, and sometimes inconclusive. The growing need for accurate, minimally invasive, and patient-friendly diagnostic tools is pushing innovation in biomarkers, molecular testing, and imaging technologies. These advancements aim not only to detect the disease earlier but also to monitor recurrence and treatment response with higher specificity and sensitivity. As awareness of urothelial carcinoma rises among clinicians and the public, demand for improved diagnostic capabilities is becoming a cornerstone of urologic oncology care.

How Are Technological Advancements Redefining Urothelial Carcinoma Diagnostic Methods?

Rapid technological developments are reshaping the diagnostic landscape for urothelial carcinoma, providing clinicians with more precise, less invasive, and data-rich tools to detect and monitor the disease. Traditional methods such as cystoscopy and urine cytology, while still widely used, are now being complemented by molecular diagnostics and high-throughput genomic profiling techniques that can detect specific mutations and gene expressions associated with urothelial carcinoma. Liquid biopsy, which involves analyzing circulating tumor DNA (ctDNA) or tumor cells in urine or blood, is gaining momentum as a non-invasive alternative that offers real-time insights into tumor biology. Innovations in next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and PCR-based assays are enabling earlier detection of carcinoma even at microscopic levels, long before visible tumors develop. Additionally, artificial intelligence and machine learning algorithms are being incorporated into diagnostic imaging and pathology workflows to assist in identifying malignancies and classifying tumor subtypes with greater accuracy. Urinary biomarker panels are being developed to offer point-of-care screening solutions, enhancing accessibility and reducing dependency on invasive procedures. These diagnostic advancements are not only improving accuracy and patient comfort but also supporting personalized treatment strategies by revealing actionable molecular targets. As diagnostic technology continues to advance, it is enabling a shift from reactive cancer care to more proactive, predictive, and precision-oriented management of urothelial carcinoma.

What Role Do Epidemiology, Risk Factors, and Healthcare Infrastructure Play in Diagnostic Demand?

The demand for urothelial carcinoma diagnostics is strongly influenced by epidemiological patterns, patient risk profiles, and the capabilities of national healthcare systems to support early detection and monitoring. Urothelial carcinoma is more prevalent in older adults and is significantly associated with modifiable risk factors such as smoking, exposure to industrial chemicals, and chronic urinary tract infections. The aging global population, particularly in high-income countries, is contributing to a rising incidence of bladder and urinary tract cancers, thereby increasing the need for widespread and routine diagnostic screening. In regions with high occupational exposure to carcinogens, including parts of Asia, Eastern Europe, and the Middle East, the diagnostic burden is magnified by delayed detection and limited access to specialized care. Conversely, in countries with robust healthcare infrastructure, such as the United States, Germany, and Japan, diagnostics are often integrated into routine urological assessments for at-risk populations, contributing to earlier detection and improved survival rates. Public health campaigns, clinical guidelines, and insurance coverage for cancer screening all play a role in determining how and when patients undergo diagnostic evaluations. Moreover, disparities in access to advanced diagnostic technologies persist between urban and rural settings, and between public and private healthcare sectors. Addressing these systemic gaps is crucial to improving diagnostic accuracy and equity across diverse population groups. As global awareness of urothelial carcinoma increases, healthcare systems are being pressured to invest in infrastructure, training, and technology to expand the reach and impact of diagnostic services.

What Key Factors Are Fueling Growth in the Urothelial Carcinoma Diagnostics Market?

The growth in the urothelial carcinoma diagnostics market is driven by a convergence of clinical, technological, and policy-level factors that reflect evolving healthcare priorities. One of the primary drivers is the global increase in bladder and urinary tract cancer cases, particularly among aging populations and individuals exposed to occupational carcinogens. This epidemiological trend is reinforcing the need for regular screening and reliable diagnostic tools. Technological innovations, including the emergence of non-invasive tests such as urinary biomarkers and liquid biopsies, are making diagnostics more patient-friendly and efficient, thus widening their adoption across clinical settings. Regulatory support for early cancer detection, coupled with reimbursement frameworks that favor preventive care, is incentivizing both public and private healthcare providers to integrate advanced diagnostic tools into routine practice. The push toward personalized medicine and targeted therapies is also stimulating demand for molecular diagnostics that can stratify patients and guide treatment decisions based on genetic and molecular profiles. Growing investments from pharmaceutical and diagnostic companies in oncology research are accelerating the development and commercialization of next-generation testing platforms. Furthermore, the rising availability of point-of-care diagnostics and telemedicine-based pathology services is expanding access in underserved and remote areas. These factors, alongside ongoing efforts to improve cancer survival outcomes and reduce healthcare costs through early intervention, are collectively driving robust and sustained growth in the global urothelial carcinoma diagnostics market.

SCOPE OF STUDY:

The report analyzes the Urothelial Carcinoma Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagent & Kits, Instruments); Test (Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test, Ureteroscopy Test); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use, Clinical Research Organizations End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Abbott Molecular (Abbott Laboratories)
  • Agilent Technologies
  • AroCell (IDL Biotech)
  • Becton Dickinson (BD)
  • Bio-Rad Laboratories, Inc.
  • Cepheid (Danaher)
  • F. Hoffmann-La Roche Ltd (Roche)
  • GE Healthcare
  • Illumina, Inc.
  • IDL Biotech
  • Olympus Corporation
  • Pacific Edge Limited
  • Philips Healthcare (Koninklijke Philips)
  • QIAGEN
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Vesica Health
  • Nucleix
  • Danaher Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Urothelial Carcinoma Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Bladder Cancer Throws the Spotlight on Early and Accurate Urothelial Carcinoma Detection
    • Growing Emphasis on Non-Invasive Diagnostics Spurs Demand for Urine-Based and Liquid Biopsy Solutions
    • Here's How Molecular and Genomic Profiling Are Driving Precision Diagnosis in Urothelial Carcinoma
    • Increasing Adoption of Fluorescence and Narrow Band Imaging Strengthens the Business Case for Enhanced Cystoscopy Tools
    • Regulatory Support for Companion Diagnostics Expands the Addressable Market for Biomarker-Driven Tests
    • Shift Toward Personalized Oncology Care Accelerates Development of Mutation-Specific Diagnostic Platforms
    • Here's the Story: How AI-Enabled Pathology and Imaging Tools Are Reshaping Diagnostic Accuracy and Workflow
    • Clinical Push for Risk Stratification in NMIBC and MIBC Generates Demand for Prognostic Diagnostic Assays
    • Rising Use of Multiplex PCR and NGS Panels Propels Growth in Molecular Testing Adoption
    • Growing Participation in Cancer Screening Programs Enhances Early Detection Rates and Diagnostic Throughput
    • Hospital and Laboratory Digitization Trends Drive Adoption of Integrated Diagnostic Information Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Urothelial Carcinoma Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Urothelial Carcinoma Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Urothelial Carcinoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Reagent & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Reagent & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Reagent & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Clinical Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Urinalysis Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Urinalysis Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Urinalysis Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Diagnostic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Molecular Diagnostic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Molecular Diagnostic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biomarker Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Biomarker Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Cell-based Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Cell-based Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Cell-based Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Imaging Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Imaging Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cystoscopy Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cystoscopy Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Cystoscopy Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Ureteroscopy Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Ureteroscopy Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Ureteroscopy Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • JAPAN
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • CHINA
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • EUROPE
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Urothelial Carcinoma Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • FRANCE
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • GERMANY
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • INDIA
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Urothelial Carcinoma Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Urothelial Carcinoma Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030
  • AFRICA
    • Urothelial Carcinoma Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Urothelial Carcinoma Diagnostics by Product - Reagent & Kits and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Urothelial Carcinoma Diagnostics by Product - Percentage Breakdown of Value Sales for Reagent & Kits and Instruments for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Urothelial Carcinoma Diagnostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Urothelial Carcinoma Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Clinical Research Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Urothelial Carcinoma Diagnostics by Test - Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Urothelial Carcinoma Diagnostics by Test - Percentage Breakdown of Value Sales for Urinalysis Test, Molecular Diagnostic Test, Biomarker Test, Cell-based Test, Imaging Test, Cystoscopy Test and Ureteroscopy Test for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제